Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KAT2B | Q92831 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL434996 | 0.78 | NPSR1 (0.58) | HPGDMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL8691818 | 0.78 | MAPK1 (0.42) | HPGDMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL19869863 | 0.76 | MEN1 (0.47) | HPGDMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL17559135 | 0.76 | KAT2B (0.50) | HPGDMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL8535608 | 0.76 | HPGD (0.47) | HPGDMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL31091769 | 0.76 | KAT2B (0.50) | HPGDMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL13829800 | 0.76 | MAPT (0.60) | KMT2AALDH1A1LMNAL3MBTL1TBXAS1 | |
| SCHEMBL3652058 | 0.76 | ALDH1A1 (0.64) | HPGDMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL7458097 | 0.76 | SMN1; SMN2 (0.60) | HPGDMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL30319409 | 0.76 | MEN1 (0.63) | HPGDMEN1KMT2ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11059849-B2 | Modified nucleotides for synthesis of nucleic acids, a kit containing such nucleotides and their use for the production of synthetic nucleic acid sequences or genes | DNA SCRIPT (FR) | 2021-07-13 | — | — | US | disclosed |
| CN-107074903-B | Modified nucleotides for nucleic acid synthesis, kits containing such nucleotides and uses thereof for producing synthetic nucleic acid sequences or genes | DNA斯克瑞普特公司 | 2021-06-08 | — | — | CN | disclosed |
| EP-3339314-B1 | MODIFIED NUCLEOTIDES FOR NUCLEIC ACID SYNTHESIS, KIT COMPRISING SUCH NUCLEOTIDES AND USE THEREOF FOR THE PRODUCTION OF SYNTHETIC NUCLEIC ACID SEQUENCES OR GENES | DNA SCRIPT (FR) | 2021-05-05 | — | — | EP | disclosed |
| US-20200231619-A1 | MODIFIED NUCLEOTIDES FOR SYNTHESIS OF NUCLEIC ACIDS, A KIT CONTAINING SUCH NUCLEOTIDES AND THEIR USE FOR THE PRODUCTION OF SYNTHETIC NUCLEIC ACID SEQUENCES OR GENES | DNA SCRIPT SAS (FR) | 2020-07-23 | — | — | US | disclosed |
| EP-3339314-A1 | MODIFIED NUCLEOTIDES FOR NUCLEIC ACID SYNTHESIS, KIT COMPRISING SUCH NUCLEOTIDES AND USE THEREOF FOR THE PRODUCTION OF SYNTHETIC NUCLEIC ACID SEQUENCES OR GENES | DNA Script (FR) | 2018-06-27 | — | — | EP | disclosed |
| CN-102971335-B | Reversibly terminating primer extension reagents | 史蒂芬·阿尔伯特·本纳 | 2016-06-29 | — | — | CN | disclosed |
| US-8809360-B2 | Use of a pyridine compound for the preparation of a medicament for the treatment of skin lesions | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-08-19 | — | — | US | disclosed |
| US-8809360-B2 | Use of a pyridine compound for the preparation of a medicament for the treatment of skin lesions | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-08-19 | — | — | US | disclosed |
| US-8481580-B2 | interleukin 1, 12, tumor necrosis factor alpha, and trigger interferon- gamma antagonist; antiinflammatory , antidiabetic agent, autoimmune disorders; active side chain moiety (5-R-hydroxyhexyl) of lisofyllin, greater potency and oral bioavailability than lisofylline | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-20130137693-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2013-05-30 | — | — | US | disclosed |
| US-5489677-A | NUCLEASE RESISTANT OLIGONUCLEOTIDE ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 1996-02-06 | — | — | US | disclosed |
| WO-1995018136-A1 | BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGS AND SOLID PHASE SYNTHESIS THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 1995-07-06 | — | — | WO | disclosed |
| EP-0649429-A1 | HETEROATOMIC OLIGONUCLEOSIDE LINKAGES | ISIS PHARMACEUTICALS, INC. (US) | 1995-04-26 | — | — | EP | disclosed |
| US-5386023-A | Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling | ISIS PHARMACEUTICALS (US) | 1995-01-31 | — | — | US | disclosed |
| WO-1994022893-A1 | OLIGONUCLEOSIDE LINKAGES CONTAINING ADJACENT NITROGEN ATOMS | ISIS PHARMACEUTICALS, INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1994022883-A1 | BACKBONE MODIFIED OLIGONUCLEOTIDES AND THEIR PREPARATION | ISIS PHARMACEUTICALS, INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1994022886-A1 | HETEROATOMIC OLIGONUCLEOSIDE LINKAGES | ISIS PHARMACEUTICALS, INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1994022894-A1 | BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGS AND PREPARATION THEREOF THROUGH RADICAL COUPLING | ISIS PHARMACEUTICALS, INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1994022454-A1 | OLIGONUCLEOSIDE LINKAGES CONTAINING ADJACENT OXYGEN AND NITROGEN ATOMS | ISIS PHARMACEUTICALS, INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1994000467-A1 | HETEROATOMIC OLIGONUCLEOSIDE LINKAGES | ISIS PHARMACEUTICALS, INC. (US) | 1994-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11059849-B2 | Modified nucleotides for synthesis of nucleic acids, a kit containing such nucleotides and their use for the production of synthetic nucleic acid sequences or genes | RNGTT, RNMT, PNP | HPGD 1364/4885MEN1 2486/4885KMT2A 841/4885 |
| US-20130137693-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | IAPP, RNASE1, CTSA | HPGD 2591/4885MEN1 2296/4885KMT2A 3484/4885 |
| US-20200231619-A1 | MODIFIED NUCLEOTIDES FOR SYNTHESIS OF NUCLEIC ACIDS, A KIT CONTAINING SUCH NUCLEOTIDES AND THEIR USE FOR THE PRODUCTION OF SYNTHETIC NUCLEIC ACID SEQUENCES OR GENES | RNGTT, RNMT, PNP | HPGD 1364/4885MEN1 2486/4885KMT2A 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.